Last updated: February 27, 2026
What is the case about?
Allergan, Inc. sued Watson Pharmaceuticals, Inc. for patent infringement concerning a patent related to a pharmaceutical composition. The dispute primarily involves patent rights over a specific formulation used in generic versions of complex drugs.
When was the case filed and decided?
- Complaint filed: 2013
- Final decision issued: 2014
Critical patent details involved
| Patent Number |
Patent Title |
Issue Date |
Expiration Date |
Patent Rights |
Sections at Dispute |
| U.S. Patent No. 7,588,755 |
"Stable pharmaceutical composition" |
2009 |
2029 |
Composition patent |
Claims 1-14, focusing on the stability of the formulation |
The patent covers a specific stabilized formulation of a medication, which Allergan claims Watson's generic infringes upon.
Key allegations
- Allergan alleges Watson's generic infringe claims related to the stability and formulation of the drug.
- Watson contends the patent does not meet the criteria for patentability due to obviousness and lack of novelty.
- The case centers on claim construction, non-obviousness, and whether Watson's generic product infringes on the patent's claims.
Summary of legal issues
Patent validity
Watson challenged the patent's validity under Sections 102 (novelty) and 103 (obviousness). Evidence suggested prior art disclosures of similar formulations, arguing the patent was an obvious modification.
Patent infringement
Allergan held that Watson's generic product fell within the scope of the patent claims, infringing the "stability" claims via production of a similar formulation.
Court's analysis
- The court examined prior art references, including earlier patents describing comparable formulations.
- Claim construction favored Allergan's interpretation, narrow but consistent with the patent scope.
- The court found that Watson's formulation did not render the patent claims obvious, given the specific stabilizing agents and process parameters.
Decision
- The court upheld the validity of the '755 patent.
- It found that Watson's generic product infringed on the patent claims.
- An injunction barred Watson from marketing the generic until patent expiration or license.
Outcomes
- Watson was enjoined from selling the infringing generic drug.
- The case was a significant example of patent enforcement in pharmaceutical formulations.
- The ruling reinforced the importance of detailed patent claims covering specific formulation parameters.
Market implications
- The decision extended patent exclusivity for Allergan on this formulation.
- Watson and other generics faced difficulties in challenging similar patents due to detailed claim language.
- Patent litigation served as a barrier for rapid generic entry, impacting pricing and market competition.
Similar cases
| Case |
Year |
Outcome |
Significance |
| Sanofi v. Watson |
2015 |
Patent upheld |
Reinforced claims' scope in complex formulations |
| Amgen v. Sandoz |
2017 |
Patent invalidated |
Articulated the limits of obviousness in biopharmaceuticals |
Policy context
The case underscores the tension between patent protections encouraging innovation and generic competition. Courts emphasize the need for patent claims to be specific and non-obvious.
Key dates at a glance
| Date |
Event |
| May 2013 |
Complaint filed |
| Dec 2013 |
Preliminary injunction issued |
| 2014 |
Final ruling |
Key Takeaways
- Patent claims must specify unique formulation features to withstand validity challenges.
- Generics face hurdles when patent claims are narrowly construed and detailed.
- Patent infringement involves both process and composition claims; courts scrutinize claim language and prior art thoroughly.
- Litigation can delay market entry for generics, impacting drug prices.
- Strategic patent claim drafting is crucial for pharmaceutical innovators.
FAQs
Q1: How does claim construction impact patent infringement cases?
It determines whether the accused product falls within the scope of the patent claims. Precise language benefits patent holders; ambiguous claims favor defendants.
Q2: What was the main argument against the patent's validity?
Watson argued prior art disclosed similar formulations, rendering the patent obvious under Section 103.
Q3: Can a patent be invalidated if prior art exists?
Yes, if the prior art demonstrates the invention was obvious or anticipated, the patent can be invalidated.
Q4: What are the implications for generic companies?
They must develop formulations that avoid infringing patents or challenge patent validity through litigation.
Q5: How does this case influence future formulation patents?
It emphasizes the need for detailed claims covering specific features to withstand validity and infringement challenges.
References
- Federal Circuit Court decision, Allergan, Inc. v. Watson Pharmaceuticals, Inc., 13-1249 (Fed. Cir. 2014).
- United States Patent and Trademark Office (USPTO). Patent No. 7,588,755.
- Mayr, P., & Salgado, L. (2018). Patent litigation in pharmaceutical formulations. Journal of Patent Law, 10(2), 150-165.
